Prosecution Insights
Last updated: April 19, 2026

Examiner: REYNOLDS, FRED H

Tech Center 1600 • Art Units: 1654 1658 1675

This examiner grants 33% of resolved cases

Performance Statistics

33.0%
Allow Rate
-27.0% vs TC avg
919
Total Applications
+39.5%
Interview Lift
1055
Avg Prosecution Days
Based on 815 resolved cases, 2023–2026

Rejection Statute Breakdown

3.9%
§101 Eligibility
13.2%
§102 Novelty
33.3%
§103 Obviousness
26.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17293840 METHODS AND COMPOSITIONS RELATED TO TARGETING FFAR2 AND ILC3 POPULATIONS FOR THE TREATMENT OF A GASTROINTESTINAL DISEASE Non-Final OA PRESIDENT AND FELLOWS OF HARVARD COLLEGE
16972800 Compositions of Transforming Growth Factor-Beta Type III Receptor and Uses for Ossification Final Rejection Emory University
17597925 ANTIMICROBIAL THERAPY THROUGH THE COMBINATION OF PORE-FORMING AGENTS AND HISTONES Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17583549 Composition for and Method of Improving Tissue Performance Non-Final OA OHIO STATE INNOVATION FOUNDATION
17006591 PROTEASE SENSITIVE GVPC AND RELATED GAS VESICLE GENE CLUSTERS, EXPRESSION SYSTEMS, CONSTRUCTS, VECTORS, GENETIC CIRCUITS, CELLS, COMPOSITIONS, METHODS AND SYSTEMS FOR CONTRAST-ENHANCED IMAGING Non-Final OA California Institute of Technology
17403357 COMPOSITIONS COMPRISING A DELIVERY AGENT AND PREPARATION THEREOF Final Rejection Novo Nordisk A/S
18252073 Peptide Inhibitors of Human Mitochondrial Fission Protein 1 and Methods of Use Non-Final OA The Medical College of Wisconsin, Inc.
18148653 NOVEL PROTAC CHIMERIC COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING, AMELIORATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION Non-Final OA POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION
18044962 PTPSIGMA-FC FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Non-Final OA IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
17263689 METHODS AND MATERIALS FOR TREATING CANCER Final Rejection Board of Regents, The University of Texas System
18551271 NOVEL PEPTIDE-OLIGONUCLEOTIDE CONJUGATE AND USE THEREOF Non-Final OA KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
17619175 TARGETING MELANOCORTIN 3 RECEPTOR FOR TREATMENT/PREVENTION OF EATING, METABOLISM, AND/OR EMOTIONAL DISORDERS Final Rejection The Regents of the University of Michigan
16453242 TREATMENT OF AGE RELATED MACULAR DEGENERATION WITH A SMALL ACTIVE CHOROIDAL NEOVASCULARIZATION LESION Non-Final OA Bayer HealthCare LLC
17633631 METHODS OF MAKING INCRETIN ANALOGS Final Rejection ELI LILLY AND COMPANY
18664616 SILK FIBROIN-CONTAINING COMPOSITION AND METHODS OF USE THEREOF Non-Final OA Georgetown University
17620467 COMPOSITES AND USES THEREOF Non-Final OA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
16198019 CARDIAC FIBROBLAST-DERIVED EXTRACELLULAR MATRIX AND INJECTABLE FORMULATIONS THEREOF FOR TREATMENT OF ISCHEMIC DISEASE OR INJURY Final Rejection Wisconsin Alumni Research Foundation
17631072 COMPOSITION FOR PROMOTING GROWTH OR SUPPRESSING DECREASE OF MESENCHYMAL STEM CELLS Final Rejection OSAKA UNIVERSITY
18259092 METHODS OF TREATING, DIAGNOSING AND PREDICTING PROGNOSIS OF SEPSIS Non-Final OA University of Rochester
17282883 METHODS OF REDUCING TYPE 2 CYTOKINE-MEDIATED INFLAMMATION USING NEUROMEDIN PEPTIDES Final Rejection Rutgers, The State University of New Jersey
18731097 PEPTIDES AND METHODS OF TRANSPLANTATION AND RESTORATIVE ORGAN FUNCTION Final Rejection Prince Biotech, LLC
18590539 TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF Non-Final OA SUN PHARMACEUTICAL INDUSTRIES LIMITED
18269716 METHOD FOR PRODUCING LIPIDIC PEPTIDE Non-Final OA NISSAN CHEMICAL CORPORATION
17606174 METHOD FOR PRODUCING PEPTIDE COMPOUND Final Rejection NISSAN CHEMICAL CORPORATION
17765707 PEPTIDE BASED COSMETIC OR DERMATOLOGICAL TREATMENT OF THE SKIN AND ITS APPENDAGES Final Rejection Sederma
18639343 POLYMERIC FORMS OF H-NOX PROTEINS Final Rejection c/o Omniox, Inc.
18272549 DUAL-ADMINISTRATION METHODS FOR TREATING RESPIRATORY DISTRESS Non-Final OA THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY
17626625 PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION CONTAINING CYCLOSPORINE Final Rejection PHARMATHEN S.A.
17251079 NON-VITAL WHEAT PROTEIN AND ITS PRODUCTION PROCESS Final Rejection ROQUETTE FRERES
18612989 PHARMACEUTICAL USE Final Rejection ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month